Vitamin D, Sunlight, and the epidemiology of prostate cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 1, 2013, Pages 45-57

  Schwartz, Gary G ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

25 hydroxyvitamin D; Calcium; Epidemiology; Prostate cancer; Sunlight; VDR; Vitamin D

Indexed keywords

CALCITRIOL; CALCIUM; COLECALCIFEROL; MELANIN; PROSTATE SPECIFIC ANTIGEN; VITAMIN D; VITAMIN D RECEPTOR;

ARTICLE; ASYMPTOMATIC DISEASE; CALCIUM INTAKE; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; DISEASE ASSOCIATION; ECOLOGY; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERPARATHYROIDISM; META ANALYSIS (TOPIC); OCCUPATIONAL HEALTH; PREVALENCE; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE EPITHELIUM; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SOLAR RADIATION; SUNLIGHT; TUMOR INVASION; ULTRAVIOLET RADIATION; VITAMIN D DEFICIENCY;

EID: 84876687406     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152013804487344     Document Type: Article

References (137)

1. Schwartz, G.G.; Hulka, B.S. Is vitamin D deficiency a risk factor for prostate cancer (Hypothesis)? Anticancer Res., 1990, 10, 1307-1311.
2. Schwartz, G.G. Vitamin D and intervention trials in prostate cancer: From theory to therapy. Ann. Epidemiol., 2009, 19, 96-102.
3. Beer, T.M.; Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res., 2006, 26, 2647-2651.
4. Krishan, A.V.; Feldman D. Molecular pathways mediating the antiinflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer, 2010, 17, R19-R38.
5. Robinson, W.S. Ecological correlations and the behavior of individuals. Am. Sociol. Rev., 1950, 15, 351-357.
6. Schwartz, G.G.; Porta, M. Vitamin D, ecologic studies and endometrial cancer. Prev. Med., 2007, 45, 323-324.
7. Ernster, V.L. Nested case-control studies. Prev. Med., 1994, 23, 587-590.
8. Kurihara, M.; Aoki, K.; Hismamichi, S. (eds). Cancer Mortality Statistics in the World, 1950-1985, Nagoya, Japan: University of Nagoya Press, 1989.
9. Yatani, R.; Chigusa, I.; Akazaki, K.; Stermmerman, G.; Welsh, R.; Correa, P. Geographic pathology of latent prostate carcinoma. Int. J. Cancer, 1984, 29, 611-616.
10. Sakr, W.A.; Haas, G.P.; Cassin, B.F.; Pontes, J.E.; Crissman, J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young adult patients. J. Urol., 1993, 150, 379-385.
11. Breslow, N.; Chan, C.W.; Dhom, G.; Drury, R.A.; Franks, L.M.; Gellei, B.; Lee, Y.S.; Lundberg, S.; Sparkle, B.; Sternby, N.H.; Tulinius, H. Latent carcinoma of the prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int. J. Cancer, 1977, 20, 379-385.
12. Lin, K.; Lipsitz, R.; Miller, T.; Janakiraman, S.; U.S. Preventive Services Task Force. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann. Intern. Med., 2008, 149, 192-199.
13. Andriole, G.L.; Grubb, R.L. 3rd; Buys, S.S.; Chia, D.; Church, T.R.; Fouad, M.N.; Gelmann, E.P.; Kvale, P.A.; Reding, D.J.; Weissfeld, J.L.; Yokochi, L.A.; O'Brien, B.; Clapp, J.D.; Rathmell, J.M.; Riley, T.L.; Hayes, R.B.; Kramer, B.S.; Izmirlian, G.; Miller, A.B.; Pinsky, P.F.; Prorok, P.C.; Gohagan, J.K.; Berg, C.D.; PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. New Engl. J. Med., 2009, 360, 1310-1319.
14. Etzioni, R.; Cha, R.; Feurer, E.J.; Davidov, O. Asymptomatic incidence and duration of prostate cancer. Am. J. Epidemiol., 1998, 148, 775-785.
15. Hanchette, C.L.; Schwartz, G.G. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation. Cancer, 1992, 70, 2861-2869.
16. Schwartz, G.G.; Hanchette, C.L. UV, latitude, and prostate cancer mortality: All sunlight is not the same (United States) Cancer Causes Control, 2006, 17, 1091-1101.
17. Miller, G.J.; Stapleton, G.E.; Ferrara, J.A.; Lucia, M.S.,; Pfister, S.; Hedlund, T.E.; Upadhya, P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α, 25-dihydroxyvitamin D3. Cancer Res., 1992, 52, 515-520.
18. Moreno, J., Krishnan, A.V., Feldman, D. Molecular mechanisms mediating the anti-proliferative effects of Vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol., 2005, 97, 31-36.
19. Schwartz, G.G.; Wang, M.-H., Zhang, M., Singh, R.K.; Siegal, G.P. 1α, 25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol. Biomarkers Prev., 1997, 6, 727-732.
20. Sung, V.; Feldman D. 1, 25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell. Endocrinol., 2000, 164, 133-143.
21. Lokeshwar, B.L.; Schwartz, G.G.; Selzer, M.G.; Burnstein, KL; Zhuang, S.-H.; Block, N.L.; Binderup, L. Inhibition of prostate cancer metastasis in vivo: A comparison of 1, 25-Dihydroxyvitamin D (calcitriol) and EB1089. Cancer Epidem. Biomarkers Prev., 1999, 8, 241-248.
22. Bao, B.Y.; Yeh, S.D.; Lee, Y.F. 1α, 25-Dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis, 2006, 27, 32-42.
23. Bao, Y.-B.; Yao, J.; Lee, Y-F. 1α-Dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis, 2007, 27, 1883-1889.
24. Haddad, J.G. Jr.; Hahn, T.J. Natural and synthetic sources of circulating 25-Hydroxyvitamin D in man. Nature, 1973, 244, 525-527.
25. Holick, M.F. Photobiology of vitamin D, In: Feldman D, Gloriexux FH, Pike JW, eds. Vitamin D, 1st ed. San Diego, CA:Academic Press, 33-39, 1995.
26. DeGroot, L.J. (ed.) Endocrinology, 2nd edition, Philadelphia, W.B. Saunders, 1989.
27. Chesney, R.W.; Rosen, J.F.; Hanstra, A.J.; Smith, C.; Mahaffey, K.; DeLuca, H.F. Absence of seasonal variations in serum concentrations of 1, 25-dihydroxyvitamin D despite a rise in 25- hydroxyvitamin D in summer. J. Clin. Endocrinol. Metab., 1981, 53, 139-143.
28. Schwartz, G.G.; Whitlatch, L.W.; Chen, T.C.; Lokeshwar, B.L.; Holick, M.F. Human prostate cells synthesize 1, 25-Dihydroxyvitamin D3 from 25-Hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 1998, 7, 391-395.
29. Barreto, A.; Schwartz, G.G.; Woodruff, R.; Cramer, S.D. 25- Hydro-xyvitamin D3, the prohormonal form of 1, 25- Dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev., 2000, 9, 265-270.
30. Young, M.V.; Schwartz, G.G.; Wang, L.; Jamieson, D.P.; Whitlatch, L.W.; Flanagan, J.N.; Lokeshwar, B.L.; Holick, M.F.; Chen, TC. The prostate 25-Hydroxyvitamin D-1α-Hydroxylase is not influenced by parathyroid hormone and calcium: Implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis, 2004, 25, 967-971.
31. Hsu, J.Y.; Feldman, D.; McNeal, J.E.; Peehl, D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3- induced growth inhibition. Cancer Res., 2001, 61, 2852-2856.
32. Whitlatch, L.W.; Young, M.V.; Schwartz, G.G.; Flanagan, J.N.; Burnstein, K.L.; Lokeshwar, B.L.; Rich, E.S.; Holick, M.F.; Chen, T.C. 25-Hydroxyvitamin D-1-alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol., 2002, 81, 135-140.
33. Chen, T.C., Schwartz, G.G.; Burnstein, K.L.; Lokeshwar, B.L.; Holick, M.F. The use of 25-Hydroxyvitamin D3 and 19-nor-1, 25- Dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin. Cancer Res., 2000, 6, 901-908.
34. Haussler, M.R.; Jurutka, P.W.; Hseih, J.C.; Thompson, P.D.; Selznick, S.H.; Hausler, C.A.; Whitfield, G.K. New understanding of the molecular mechanism of receptor-mediated genomic actions of vitamin D hormone. Bone, 1995, 17, 33S-38S.
35. Zhuang, S.-H.; Schwartz, G.G.; Cameron, D.; Burnstein, K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cells. Mol. Cell. Endocrin., 1997, 126, 83-90.
36. Miller, G.J.; Stapleton, G.E.; Hedlund, T.E.; Moffatt, K.A. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α, 25-Dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res., 1995, 1, 997-1003.
37. Kivineva, M.; Bläuer, M.; Syvälä, H.; Tammela, T.; Tuohimaa, P. Localization of 1, 25-Dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J. Steroid Biochem. Mol. Biol., 1998, 66, 121-127.
38. Blutt, S.E.; Weigel, N.L. Vitamin D and prostate cancer. Proc. Soc. Exp. Biol. Med., 1999, 221, 89-98.
39. Miller, G.J. Vitamin D and prostate cancer: Biological interactions and clinical potentials. Cancer Metastasis Rev., 1998, 17, 353-360.
40. Krill, D.; DeFlavia, P.; Dhir, R.; Luo, J.; Becich, M., et al. Expression patterns of vitamin D receptor in human prostate. J. Cell Biochem., 2001, 82, 566-572.
41. Schwartz, G.G. Vitamin D and the epidemiology of prostate cancer. Semin. Dialysis, 2005, 19, 276-89.
42. Heaney, R.P.; Davies, K.M.; Chen, T.C.; Holick, M.F.; Barger- Lux, M.J. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr., 2003, 77, 204-210.
43. Kafadar, K. Geographic trends in prostate cancer mortality: An application of spatial smoothers and the need for adjustment. Ann. Epidemiol., 1997, 7, 35-45.
44. Grant, W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer, 2002, 94, 1867-75.
45. Bosco, F.P.; Schymura, M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer, 2006, 10, 264.
46. St-Hilaire, S.; Mannel, S.; Commendador, A.; Mandal, R.; Derryberry, D. Correlations between meteorologic parameters and prostate cancer. Int. J. Health Geogr., 2010, 9, 19.
47. Schwartz, G.G.; Hanchette, C.L. UV, latitude, and prostate cancer mortality: All sunlight is not the same (United States). Cancer Causes Control, 2006, 17, 1091-101.
48. Webb, A.R.; Kline, L.; Holick, M.F. Influence of season and latitude on the cutaneous synthesis of vitamin D3. Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab., 1988, 67, 373-378.
49. Grant, W.B. An ecological study of cancer incidence and mortality rates in France with respect to latitude, an index for vitamin D production. Dermato-Endocrinol., 2010, 2, 62-67.
50. Loke, T.W.; Svdfi, D.; Khadra, M. Prostate cancer incidence in Australia correlates inversely with solar radiation. B.J.U. International, 2011, 109, Suppl. 2, 66-70.
51. Gandini, S.; Boniot, M.; Haukka, J.; Byrnes, G.; Cox, B.; Sneyd, M.J.; Mullie, P.; Autier, P. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer, 2010, epub ahead of print.
52. Yin, H.; Raum, E.; Haug, U.; Arndt, V.; Brenner, H. Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol., 2009, 33, 435-445.
53. Corder, E.H.; Guess, H.A.; Hulka, B.S.; Friedman, G.D.; Sadler, M.; Vollmer, R.T.; Lobaugh, B.; Drezner, M.K.; Vogelman, J.H.; Orentreich, N. Vitamin D and prostate cancer: a prediagnoistic study with stored sera. Cancer Epidemiol. Biomarkers Prev., 1993, 2, 467-472.
54. Ahonen, M.H.; Tenkanen, L.; Teppo, L.; Hakama, M.; Tuohimaa, P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control, 2000, 11, 847-52.
55. Nomura, A.M.; Stemmermann, G.N.; Lee, J.; Kolonel, L.N.; Chen, T.C, Turner, A.; Holick, M.F. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control, 1998, 9, 425-432.
56. Braun, M.M.; Helzlsouer, K.J.; Hollis, B.W.; Comstock, G.W. 1995 Prostate cancer and prediagnosic levels of serum vitamin D metabolites (Maryland, United States). Cancer Cause Control, 1995, 9, 425-3.
57. Jacobs, E.T.; Giuliano, A.B.; Martinez, M.E.; Hollis, B.W.; Reid, M.E., Marshall, J.R. Plasma levels of 25-hydroxyvitamin D, 1, 25- Dihydroxyvitamin D and the risk of prostate cancer. J. Steroid Biochem. Mol. Biol., 2004, 89-90, 533-537.
58. Gann, P.H.; Ma, J.; Hennekens, C.H.; Hollis, B.W.; Haddad, J.G.; Stampfer, M.J. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 1996, 5, 121-126.
59. Platz, E.A.; Leitzmann, M.F.; Hollis, B.W. Plasma 1, 25- dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control, 2004, 15, 255-265.
60. Barnett, C.M.; Nielson, C.M.; Shannon, J.; Chan, J.M.; Shikany, J.M.; Bauer, D.C.; Hoffman, A.R.; Barrett-Conner, E.; Orwoll, E.; Beer, T.M. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control, 2010 DOI.1007/s10552-010-9557-y.
61. Park, S.-Y.; Cooney, R.V.; Wilkens, L.R.; Murphy, S.P.; Henderson, B.E.; Kolonel, L.N. Plasma 25-hydroxyvitamin D and prostate cancer risk: The Multiethnic Cohort. Eur. J. Cancer, 2010, 46, 932-936.
62. Holick, M.F. Vitamin D deficiency. New Engl. J. Med., 2007, 357, 266-281.
63. Tuohimaa, P.; Tenkanen, L.; Ahonen, M.; Lumme, S.; Jellum, E.; Hallmans G.; Stattin, P.; Harvei, S.; Hakulinen, T.; Luostarinen, T.; Dillner, J.; Lehtinen, M.; Hakama, M. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer, 2004, 108, 104-8.
64. Ahn, J.; Peters, U.; Albanes, D.; Purdue, M.P.; Abnet, C.C.; Chaterjee, N.; Horst, R.L.; Hollis, B.W.; Huang, W.Y.; Shikany, J.M.; Hayes, R.B.; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. Serum vitamin D concentrations and prostate cancer risk: A nested case-control study. J. Natl. Cancer Inst., 2008, 100, 796-804.
65. Travis, R.C.; Crowe, F.L.; Ellen, N.E.; Appleby, P.N.; Roddam, A.W.; Tjønneland, A.; Olsen, A.; Linseisen, J.; Kaaks, R.; Boeing, H.; Kröger, J.; Trichopoulou, A.; Dilis, V.; Trichopoulos, D.; Vineis, P.; Palli, D.; Tumino, R.; Sieri, S.; Bueno-de-Mesquita, H.B.; van Duijnhoven, F.J.; Chirlaque, M.D.; Barricarte, A.; Larrañaga, N.; González, C.A.; Argüelles, M.V.; Sánchez, M.J.; Stattin, P.; Hallmans, G.; Khaw, K.T.; Bingham, S.; Rinaldi, S.; Slimani, N.; Jenab, M.; Riboli, E.; Key, T.J. Serum vitamin D and risk of prostate cancer in a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) Am. J. Epidemiol., 2009, 169, 1223-1232.
66. Gilbert, R.; Metcalfe, C.; Fraser, W.D.; Donovan, J.; Hamdy, F.; Neal, D.E.; Athene Lane, J.; Martin, R.M. Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int. J. Cancer 2011, in press.
67. Schwartz, G.G. Prostate cancer, serum Parathyroid Hormone and the progression of skeletal metastases. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 478-83.
68. Albanes, D.; Mondul, A.M.; Yu, K.; Parisi, D.; Horst, R.L.; Virtamo, J.; Weinstein, S.J. Serum 25-Hydroxy Vitamin D and prostate cancer risk in a large nested case-control study. Cancer Epidemiol. Biomarkers Prev., 2011, 20, 1850-1860.
69. Schwartz, G.G. Circulating vitamin D and risk of prostate cancer - Letter. Cancer Epidemiol. Biomarkers Prev. 2012, 21, 246.
70. Tretli, S.; Hernes, E.; Berg, J.P.; Hestvik, U.E.; Robsahm, T.E. Association between serum 25(OH)D and death from prostate cancer. Br. J. Cancer, 2009, 100, 450-454.
71. Fang, F.; Kasperyk, J.L.; Shui, I.; Hendricson, W.; Hollis, B.W.; Fall, K.; Ma, J.; Gaziano, J.M.; Stampfer, M.J.; Mucci, L.A.; Giovannucci, E. Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PLoS One, 2011, 6, e18625.
72. Shui, I.M.; Mucci, L.A.; Kraft, P.; Tamimi, R.M.; Linstrom, S.; Penney, K.L., Nimptsch, K.; Hollis, B.W.; Dupre, N.; Platz, E.A.; Stampfer, M.J.; Giovannucci, E. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: A prospective nested case-control study. J. Natl. Cancer Inst. 2012, 104, 1-10.
73. Lips, P. Which circulating level of 25-hydroxyvitamin D is appropriate? J. Steroid Biochem. Mol. Biol. 2004, 89-90, 611-614.
74. Gilbert, R.; Martin, R.M.; Beynon, R.; Harris, R.; Savovic, J.; Zuccolo, L.; Bekkering, G.E.; Fraser, W.D.; Sterne, J.D.; Metcalfe, C. Associations of circulating and dietary vitarmin D with prostate cancer risk: A systematic review and dose-response meta-analysis. Cancer Causes Control, 2011, 22, 319-340.
75. Luscombe, C.J.; Fryer, A.A.; French, M.F.; Liu, S.; Saxby, M.; Jones, P.W.; Strange, R.C. Exposure to ultraviolet radiation: Association with susceptibility and age at presentation with prostate cancer. Lancet, 2001, 358, 641-642.
76. Luscombe, C.J.; French, M.E.; Siu, S.; Saxby, M.R.; Jones, P.W.; Fryer, A.A.; Strange, R.C. Prostate cancer risk: Associations with ultraviolet radiation, tyrosinase and melanocortin-1 receptor genotypes. Br. J. Cancer, 2001, 85, 1504-1509.
77. Rukin, N.; Blagojevic, M.; Luscombe, C.J.; Liu, S.; Saxby, M.; Ramachandran, S.; Fryer, A.A.; Jones, P.W.; Strange, R.C. Associations between timing of exposure to ultraviolet radiation, Tstage and survival in prostate cancer. Cancer Detect. Prevent., 2007, 31, 443-449.
78. Walsh, P.C.; Worthington J.F. 1995 The Prostate: A Guide for Men. Baltimore, MD; Johns Hopkins University Press.
79. Freedman, D.M.; Dosemeci, M.; McGlynn, K. Sunlight and mortality from breast, ovarian, colon, prostate, and non-melanoma skin cancer: a composite death certificate based case-control study. Occup. Environ. Med. 2002, 59, 257-262.
80. Weinrich, S.; Ellison, G.; Weinrich, M.; Ross, K.; Reis-Starr, C. Low sun exposure and elevated serum prostate specific antigen in African American and Caucasian men. Am. J. Health Studies, 2001, 17, 148-150.
81. John, E.M.; Dreon, D.M.; Koo, J.; Schwartz, G.G. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J. Steroid Biochem. Mol. Biol., 2004, 89-90, 549-552.
82. Schwartz, G.G. Multiple sclerosis and prostate cancer: What do their similar geographies suggest? Neuroepidemiology, 1992, 11, 244-254.
83. John, E.M.; Schwartz, G.G.; Koo, J.; Van Den Berg, D.; Ingles, S.A. Solar exposure, vitamin D gene polymorphisms and risk of advanced prostate cancer. Cancer Res., 2005, 65, 5470-5479.
84. Giovannucci, E.; Liu, Y.; Rimm, E.B.; Hollis, B.W.; Fuchs, C.S.; Stampfer, M.J.; Willett, W.C. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl. Cancer Inst. 2006, 98, 451-459.
85. Robsahm, T.E.; Tretli, S.; Dahlback, A.; Moan, J. Vitamin D3 from sunlight may improve the prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes Control, 2004, 15, 149-158.
86. de Vries, D.; Soerjomataram, I.; Houterman, S.; Louwnam, M.W.; Coebergh, J.W. Decreased risk of prostate cancer after skin cancer diagnosis: A protective role of ultraviolet radiation? Am J. Epidemiol. 2007, 165, 966-72.
87. Levi, F.; Randimbison, L.; Te, V.-C.; Concono, M.M., La Vecchia, C. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int. J. Cancer, 2008, 123, 2899-2901.
88. Gilbert, R.; Metcalfe, C.; Oliver, S.E.; Whiteman, D.G.; Barin, C.; Ness, A.; Donovan, J.; Hamdy, F.; Neal, D.E.; Lane, J.A.; Martin, R.M. Life course sun exposure and risk of prostate cancer: Population-based nested case-control study and meta-analysis. Int. J. Cancer, 2009, 15, 1414-1423.
89. Nair-Shalliker, V.; Smith, D.P.; Effer, S.; Hughes, A.M.; Kaldor, J.M.; Clements, M.; Kicker, A.; Armstrong, B.K. Sun exposure may increase risk of prostate cancer in the high UV environment of New South Wales, Australia: A case-control study. Int. J. Cancer, in press.
90. Grant, W.B.; Garland, C.F. Letter. Sun exposure may increase risk of prostate cancer in the high UC environment of New South Wales, Australia: A case-control study. Int. J. Cancer, in press.
91. Lin, S-H.; Wheeler, D.; Yikyung, P.; Cahoon, E.; Hollenbeck, A.; Freedman, D.; Abnet, C. Prospective study of ultraviolet radiation exposure and risk of cancer in the U.S. Int. J. Cancer, 2012, in press.
92. Hofmann, J.N.; Yu, K.; Horst, R.L.; Hayes, R.B.; Purdue, M.P. Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 927-931.
93. Jorde, R.; Sneve, M.; Hutchinson, M.; Emaus, N.; Figenschau, Y.; Grimnes, G. Tracking of serum 25-Hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. Am. J. Epidemiol., 2010, 171, 903-908.
94. Schwartz, G.G. The "Cocaine Blues" and other problems in epidemiologic studies of vitamin D and cancer. Nutrition Reviews, 2007, 65, S75-S76.
95. Uitterlinden, A.G.; Fang, Y.; Van Meurs, J.B.J.; Pols, H.A.; Van Leeuwen, J.P. Genetics and biology of vitamin D receptor polymorphisms. Gene, 2004, 338, 143-156.
96. Raimondi, S.; Johansson, H.; Maisonneuve, P.; Gandini, S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis, 2009, 30, 1170-1180.
97. Ahn, J.; Albanes, D.; Berndt, S.I.; Peters, P.; Chatterjee, N.; Freedman, N.D.; Abnet, C.C.; Huang, W.Y.; Kibel, A.S.; Crawford, E.D.; Weinstein, S.J.; Chanock, S.J.; Schatzkin, A.; Hayes, R.B.; Prostate, Lung, Colorectal and Ovarian Trial Project Team. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis, 2009, 30, 769-776.
98. Yin, M.; Wei, S.; Wei, Q. Vitamin D Receptor genetic polymorphisms and prostate cancer risk: A meta-analysis of 36 published studies. Int. J. Clin. Exp. Med., 2009, 15, 159-175.
99. Köstner, K.; Denzer, N.; Müller, C.S.; Klein, R.; Tilgen, W.; Reichrath, J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature Anticancer Res., 2009, 29, 3511-3536.
100. Taylor, J.A.; Hirvonen, A.; Watson, M.; Pittman, G.; Mohler, J.L.; Bell, D.A. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res., 1996, 56, 4108-10.
101. Ingles, S.A.; Ross, R.K.; Yu, M.C.; Irvine, R.A.; La Pera, G.; Haile, R.W.; Coetzee, G.A. Association of prostate cancer with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst., 1997, 89, 166-170.
102. Ntais, C.; Polycarpou, A.; Ioannidid, J.P. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol. Biomarkers Prev., 2003, 12, 1395-402.
103. Bodiwala, D.; Luscombe, C.J.; French, M.E.; Liu, S.; Saxby, MF, Jones, P.W., et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. Environ. Mol. Mutagen, 2004, 43, 121-127.
104. Ma, J.; Stampfer, M.J.; Gann, P.H.; Hough, H.L.; Giovannucci, E.; Kelsey, K.T.; Hennekens, C.H.; Hunter, D.J. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol. Biomarkers Prev., 1998, 7, 385-390.
105. Li, H.; Stampfer, M.J.; Hollis, J.B.; Mucci, L.A.; Gaziano, J.M.; Hunter, D.; Giovannucci, E.L.; Ma, J. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med., 2007; 4:e103.
106. Mikhak, B.; Hunter, D.J.; Spiegelman, D.; Platz, E.A.; Hollis, B.W.; Giovannucci, E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25- Hydroxyvitamin D and 1, 25-Dihydroxyitamin D, and prostate cancer risk. Prostate, 2007, 67, 911-923.
107. Hamasaki, T.; Inatomi, H.; Katoh, T.; Matsumoto, T. Significance of vitamin D receptor gene polymorphism for risk and disease severity of prostate cancer and benign prostatic hyperplasia in Japanese. Urol. Int., 2002, 68, 226-231.
108. Holt, S.K.; Kwon, E.M.; Koopmeiners, J.S.; Lin, D.W.; Feng, Z.; Ostrander, E.A.; Peters, U.; Stanford J.L. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate, 2010, DOI 10.1002/pros. 21180.
109. Pao, J.-B.; Yand, Y.-P.; Huang, C.-N.; Huang, S.-P.; Hour, T.-C.; Chang, t.-Y.; Lan, Y.H.; Lu, T.L.; Lee, H.Z.; Juang, S.H.; Huang, C.Y.; Bao, B.Y. Vitamin D receptor gene variants and clinical outcomes after androgen-deprivation therapy for prostate cancer. World J. Urol., 2012, DOI.1007/s00345-011-0813-x.
110. Hendrickson, W.K.; Flavin, R.; Kasperzyk, J.L.; Fiorentino, M.; Fang, F.; Lis, R.; Fiore, C.; Penney, K.I., Ma, J.; Kantoff, P.W.; Stampfer, M.J.; Loda, M.; Mucci, L.A.; Giovannucci, E. Vitamin D Receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol., 2011, 29, 2378-2385.
111. Rose, D.P.; Boyar, A.P.; Wynder, E.L. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer, 1986, 58, 2363-2371.
112. Butler, L.M.; Wong, A.S.; Koh, W.P., Wang, R., Yuan, J.M.; Yu, M.C. Calcium intake increases risk of prostate cancer among Singapore Chinese. Cancer Res., 2010, 70, 4941-4948.
113. Parodi, P.W. Dairy product consumption and the risk of prostate cancer. Int. Dairy J., 2009, 19, 551-565.
114. World Cancer Research Fund/American Institute for Cancer Research 2007, Food, nutrition, physical activity, and the prevention of cancer: A global perspective Washington, DC, AICR.
115. Agency for Health Care Research and Quality. 2009, Vitamin D and Calcium: A Systematic Review of Health Outcomes. AHHRQ Publication No. 09-E015. http://www.ahrq.gov/clinic/tp/vitadcaltp.htm.
116. Straub D.S. Calcium supplementation in clinical practice: A review of forms, doses, and indications. Nutr. Clinical Pract., 2007, 22, 286-96.
117. Berndt, S.I.; Carter, H.B.; Landis, P.K.; Tucker, M.L.; Hsieh, L.J.; Metter, E.J.; Platz, E.A. Baltimore Longitudinal Study of Aging 2002 Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging. Urology, 2002, 60, 1118-23.
118. Giovannucci, E.; Lui, Y.; Stampfer, M.J.; Willett, W.C. A prospective study of calcium intake and incidence of fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 203-10.
119. Tseng, M.; Giri, V.; Watkins-Bruner, D.; Giovannucci, E. Dairy intake and 1, 25-dihydroxyvitamin D levels in men at high risk for prostate cancer. Cancer Causes Control, 2009, 20, 1947-1954.
120. Skinner, H.G.; Schwartz, G.G. 2008 Serum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 2302-2305.
121. Skinner, H.G.; Schwartz, G.G. A prospective study of total and ionized serum calcium and fatal prostate cancer. Cancer Epidemiol. Biomarkers Prev., 2009, 18, 575-578.
122. Halthur, C.; Johansson, A.L., Almquist, M.; Malm, J.,; Grönberg H, Manjer, J.; Dickman, P.W. Serum calcium and the risk of prostate cancer. Cancer Causes Control, 2009, 7, 1205-1214.
123. Murray, R.M.L.; Grill, V.; Crinis, N.; Ho, P.W.M.; Davison, J.; Pitt, P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer J. Clin. Endocrinol. Metab., 2001, 86, 511-516.
124. Flores, S.Q.; Varsavsky, M.; Valle Díaz De La Guardia, F.; Ortiz, J.L.M.; Torres, M.M., Álvarez, E.R.; Gomez A.Z. Hiperparatiroidismo secundario en el cancer de próstata avanzado. Endocrinología y Nutrición, 2010, 57, 100-104.
125. Schwartz, G.G.; Skinner, H.G. A prospective study of total and ionized serum calcium and time to fatal prostate cancer. Cancer Epidem. Biomarkers Prev., 2012, 10, 1768-1773.
126. Lin, K.I.; Chattopadhyay, N.; Bai, M.; Alvarez, R.; Dang, C.V.; Baraban, J.M.; Brown, E.M.; Ratan, R.R. Elevated extracellular calcium can prevent apoptosis via the calcium-sensing receptor. Biochem. Biophys. Res. Commun., 1998, 249, 325-310.
127. Lallet-Daher, H.; Roudbaraki, M.; Bavencoffee, A.; Mariot, P.; Gackière, F.; Bidaux, G.; Urbain, R.; Gosset, P.; Delcourt, P.; Fleurisse, L.; Slomianny, C.; Dewailly, E.; Mauroy, B.; Bonnal, J.L.; Skryma, R.; Prevarskaya, N. Intermediate-conductance Ca2+- activated K+ channels (IKca1) regulate human prostate cancer cell proliferation through a close control of calcium entry. Oncogene, 2009, 28, 1792-806.
128. Liao, J.; Schneider, A.; Datta, N.S.; McKauley, L.K. Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res., 2006, 77, 9065-9073.
129. Schwartz, G.G. Is serum calcium a biomarker of fatal prostate cancer? Future Oncology, 2009, 5, 577-580.
130. Jorde, R.; Sundsfjord, J.; Bønaa, K.H. Determinants of serum calcium in men and women. The Tromsø Study. Eur. J. Epidemiol., 2001, 17, 1117-1123.
131. Patel, A.M.; Goldfarb, S. Got calcium? Welcome to the Calcium- Alkali Syndrome. J. Am. Soc. Nephrol., Doi: 2010, 10.1681/ASN. 2010030255.
132. Kato, Y.; Sato, K.; Sata, A.; Omori, K.; Nakahima, K.; Tokinaga, K.; Obara, T.; Takano, K. Hypercalcemia induced by excessive intake of calcium supplements, presenting similar findings of primary hyperparathyroidism. Endocrine J., 2004, 51, 557-562.
133. Muldowney, W.P.; Mazbar, S.A. Rolaids-yogurt syndrome: a 1990s version of milk-alkali syndrome. Am. J. Kidney Dis., 1996, 27, 270-272.
134. Rowland, G.W.; Schwartz, G.G.; John, E.M.; Ingles, S.A. Calcium intake and prostate cancer among African-Americans: Effect modification by Vitamin D Receptor calcium absorption genotype. J. Bone & Mineral Res., published online Aug 26, 2011. DO1 10.1002/jbmr.505 (print version, Jan 2012).
135. Skinner, H.G.; Schwartz, G.G. The relation of serum Parathyroid Hormone and serum calcium to serum levels of Prostate Specific- Antigen: A population-based study. Cancer Epidemiol. Biomarkers Prev., 2009, 11, 2869-2873.
136. Engel, P.; Fagherazzi, G.; Boutten, A.; Dupré, T.; Mesrine, S.; Bouton-Ruault, M.C.; Clavel-Chapelon, F. Serum 25(OH)D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 2341-2350.
137. Heaney, R.P.; Dowell, S.; Hale, C.A.; Bendich, A. Calcium absorption varies within the reference range for serum 25- Hydroxyvitamin D. J. Am. Coll. Nutrition, 2003, 22, 142-146.